Hyphen Pharma International - Phillip Securities 2023-03-09: Assembling Multiple Growth Engines

Hyphen Pharma International - Assembling Multiple Growth Engines

  • Hyphens Pharma International (SGX:1J5)'s FY22 results exceeded expectations. FY22 revenue and PATMI were 109%/118% of our forecasts. Revenue jumped across all segments in 2H22, in part driven by pent-up demand after the re-opening. Hyphens Pharma's dividend surged by 66% to 1.11 cents.
  • - Read this at SGinvestors.io -
  • We raise FY23e earnings forecast for Hyphens Pharma by 31% to S$13.2mil and the DCF target price for Hyphens Pharma is nudged up to S$0.445 (previously S$0.43). Our BUY recommendation is maintained.
  • - Read this at SGinvestors.io -
  • A near-term headwind is the upfront costs to develop the DocMed healthcare platform.

The Positive

Strong growth in specialty pharma.

  • Read more at SGinvestors.io.

Above is the excerpt from report by Phillip Securities Research.
Clients of Phillip Capital may be the first to access the full report in PDF @ https://www.stocksbnb.com/.

Paul Chew Phillip Securities Research | https://www.stocksbnb.com/ 2023-03-09

Read also Phillip's most recent report:
2024-03-14 Hyphens Pharma International - More Visible Growth Drivers.

Previous report by Phillip:
2023-08-22 Hyphens Pharma International - Year Of Investment & Challenges.

Price targets by other brokers at Hyphens Pharma Target Prices.

Listing of research reports at Hyphens Pharma Analyst Reports.

Relevant links:
Hyphens Pharma Share Price History,
Hyphens Pharma Announcements,
Hyphens Pharma Dividends & Corporate Actions,
Hyphens Pharma News Articles


You May Also Like

SGX Stock / REIT Search


Most Read

Trust Bank God Of Fortune Referral Code PGKPSWAE Trust Bank Referral Code 🎁